Cargando…
Dengue and zika seropositivity, burden, endemicity, and cocirculation antibodies in Nigeria
INTRODUCTION: Mosquito-borne infections are of global health concern because of their rapid spread and upsurge, which creates a risk for coinfections. DENV and ZIKV are transmitted by Aedes aegypti and A. albopictus and are prevalent in Nigeria and neighbouring countries. However, their seroprevalen...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970210/ https://www.ncbi.nlm.nih.gov/pubmed/37074313 http://dx.doi.org/10.1080/07853890.2023.2175903 |
_version_ | 1784897876821803008 |
---|---|
author | Asaga Mac, Peter Tadele, Markos Airiohuodion, Philomena E. Nisansala, Thilini Zubair, Shaistha Aigohbahi, Jude Anyaike, Chukwuma Velayudha, Raman Kroeger, Axel Panning, Marcus |
author_facet | Asaga Mac, Peter Tadele, Markos Airiohuodion, Philomena E. Nisansala, Thilini Zubair, Shaistha Aigohbahi, Jude Anyaike, Chukwuma Velayudha, Raman Kroeger, Axel Panning, Marcus |
author_sort | Asaga Mac, Peter |
collection | PubMed |
description | INTRODUCTION: Mosquito-borne infections are of global health concern because of their rapid spread and upsurge, which creates a risk for coinfections. DENV and ZIKV are transmitted by Aedes aegypti and A. albopictus and are prevalent in Nigeria and neighbouring countries. However, their seroprevalence, burden, hidden endemicity and possible cocirculation are poorly understood in Nigeria. METHODS: We conducted a cross-sectional study of 871 participants from three regions of Nigeria. All serum samples were analysed using malaria RDT and the immunoblot molecular diagnostic assay recomLine Tropical Fever for the presence of arboviral antibody serological marker IgG (Mikrogen Diagnostik, Neuried, Germany) with DENV and ZIKV Nonstructural protein 1 (NS 1), DENV and ZIKV Equad (variant of the envelope protein with designated mutations to increase specificity), according to the manufacturer’s instructions. RESULTS: The overall IgG antibody seropositivity against DENV-flavivirus was 44.7% (389/871); 95% CI (41.41–47.99), while ZIKV-flavivirus was 19.2% (167/871); 95% CI (0.16–0.21), and DENV-ZIKV-flavivirus cocirculation antibody seropositivity was 6.2%5 (54/871); 95% CI (0.6–0.7) in the three study regions of Nigeria. The study cohort presented similar clinical signs and symptoms of flaviviruses (DENV and ZIKV) in all three study regions. CONCLUSION: This study highlighted an unexpectedly high antibody seropositivity, burden, hidden endemicity, and regional spread of mono- and co-circulating flaviviruses (DENV and ZIKV) in Nigeria. KEY MESSAGES: Dengue flavivirus sero-cross-reactivity drives antibody-dependent enhancement of ZIKV infection. Both viruses share common hosts (humans) and vectors (primarily Aedes aegypti), and are thus influenced by similar biological, ecological, and economic factors, resulting in epidemiological synergy. Additionally, the actual burden in epidemic and interepidemic periods is grossly or chronically unknown and underreported. Despite this trend and the potential public health threat, there are no reliable data, and little is known about these arboviral co-circulation infections. |
format | Online Article Text |
id | pubmed-9970210 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-99702102023-02-28 Dengue and zika seropositivity, burden, endemicity, and cocirculation antibodies in Nigeria Asaga Mac, Peter Tadele, Markos Airiohuodion, Philomena E. Nisansala, Thilini Zubair, Shaistha Aigohbahi, Jude Anyaike, Chukwuma Velayudha, Raman Kroeger, Axel Panning, Marcus Ann Med Infectious Diseases INTRODUCTION: Mosquito-borne infections are of global health concern because of their rapid spread and upsurge, which creates a risk for coinfections. DENV and ZIKV are transmitted by Aedes aegypti and A. albopictus and are prevalent in Nigeria and neighbouring countries. However, their seroprevalence, burden, hidden endemicity and possible cocirculation are poorly understood in Nigeria. METHODS: We conducted a cross-sectional study of 871 participants from three regions of Nigeria. All serum samples were analysed using malaria RDT and the immunoblot molecular diagnostic assay recomLine Tropical Fever for the presence of arboviral antibody serological marker IgG (Mikrogen Diagnostik, Neuried, Germany) with DENV and ZIKV Nonstructural protein 1 (NS 1), DENV and ZIKV Equad (variant of the envelope protein with designated mutations to increase specificity), according to the manufacturer’s instructions. RESULTS: The overall IgG antibody seropositivity against DENV-flavivirus was 44.7% (389/871); 95% CI (41.41–47.99), while ZIKV-flavivirus was 19.2% (167/871); 95% CI (0.16–0.21), and DENV-ZIKV-flavivirus cocirculation antibody seropositivity was 6.2%5 (54/871); 95% CI (0.6–0.7) in the three study regions of Nigeria. The study cohort presented similar clinical signs and symptoms of flaviviruses (DENV and ZIKV) in all three study regions. CONCLUSION: This study highlighted an unexpectedly high antibody seropositivity, burden, hidden endemicity, and regional spread of mono- and co-circulating flaviviruses (DENV and ZIKV) in Nigeria. KEY MESSAGES: Dengue flavivirus sero-cross-reactivity drives antibody-dependent enhancement of ZIKV infection. Both viruses share common hosts (humans) and vectors (primarily Aedes aegypti), and are thus influenced by similar biological, ecological, and economic factors, resulting in epidemiological synergy. Additionally, the actual burden in epidemic and interepidemic periods is grossly or chronically unknown and underreported. Despite this trend and the potential public health threat, there are no reliable data, and little is known about these arboviral co-circulation infections. Taylor & Francis 2023-02-22 /pmc/articles/PMC9970210/ /pubmed/37074313 http://dx.doi.org/10.1080/07853890.2023.2175903 Text en © 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Infectious Diseases Asaga Mac, Peter Tadele, Markos Airiohuodion, Philomena E. Nisansala, Thilini Zubair, Shaistha Aigohbahi, Jude Anyaike, Chukwuma Velayudha, Raman Kroeger, Axel Panning, Marcus Dengue and zika seropositivity, burden, endemicity, and cocirculation antibodies in Nigeria |
title | Dengue and zika seropositivity, burden, endemicity, and cocirculation antibodies in Nigeria |
title_full | Dengue and zika seropositivity, burden, endemicity, and cocirculation antibodies in Nigeria |
title_fullStr | Dengue and zika seropositivity, burden, endemicity, and cocirculation antibodies in Nigeria |
title_full_unstemmed | Dengue and zika seropositivity, burden, endemicity, and cocirculation antibodies in Nigeria |
title_short | Dengue and zika seropositivity, burden, endemicity, and cocirculation antibodies in Nigeria |
title_sort | dengue and zika seropositivity, burden, endemicity, and cocirculation antibodies in nigeria |
topic | Infectious Diseases |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9970210/ https://www.ncbi.nlm.nih.gov/pubmed/37074313 http://dx.doi.org/10.1080/07853890.2023.2175903 |
work_keys_str_mv | AT asagamacpeter dengueandzikaseropositivityburdenendemicityandcocirculationantibodiesinnigeria AT tadelemarkos dengueandzikaseropositivityburdenendemicityandcocirculationantibodiesinnigeria AT airiohuodionphilomenae dengueandzikaseropositivityburdenendemicityandcocirculationantibodiesinnigeria AT nisansalathilini dengueandzikaseropositivityburdenendemicityandcocirculationantibodiesinnigeria AT zubairshaistha dengueandzikaseropositivityburdenendemicityandcocirculationantibodiesinnigeria AT aigohbahijude dengueandzikaseropositivityburdenendemicityandcocirculationantibodiesinnigeria AT anyaikechukwuma dengueandzikaseropositivityburdenendemicityandcocirculationantibodiesinnigeria AT velayudharaman dengueandzikaseropositivityburdenendemicityandcocirculationantibodiesinnigeria AT kroegeraxel dengueandzikaseropositivityburdenendemicityandcocirculationantibodiesinnigeria AT panningmarcus dengueandzikaseropositivityburdenendemicityandcocirculationantibodiesinnigeria |